Evidence map›Paper›PMID 23094060›Full record

ArticlePloS one2012

Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.

Mingshun Zhang, Yanmei Jiao, Shixia Wang, Lu Zhang, Zuhu Huang, Yuxin Chen, Hao Wu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Mingshun ZhangJiangsu Province Key Laboratory in Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yanmei Jiao
Shixia Wang
Lu Zhang
Zuhu Huang
Yuxin Chen
Hao Wu
Beijing YouAn Hospital · CNJiangsu Province Hospital · CNUniversity of Massachusetts Chan Medical School · USNanjing Medical University · CN

Funding

Optimizing the immunogenicity of next generation polyvalent HIV vaccine formulatiU19AI082676 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2009 to 2016
$15.8M
Variation in HIV-1 R5 Envs: Consequences for tropism, neutralization & vaccinesP01AI082274 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CLAPHAM, PAUL R · 2009 to 2013
$9.7M
Polyvalent DNA Plus Protein HIV VaccinesR01AI065250 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LU, SHAN · 2006 to 2010
$1.9M
NIAID NIH HHS P01 AI082274NIAID NIH HHS R01 AI065250NIAID NIH HHS U19 AI082676
6 · The paper itself

Abstract

Protective antibodies play a critical role in an effective HIV vaccine; however, eliciting antibodies to block infection by viruses from diverse genetic subtypes remains a major challenge. As the world's most populous country, China has been under the threat of at least three major subtypes of circulating HIV-1 viruses. Understanding the cross reactivity and specificities of serum antibody responses that mediate broad neutralization of the virus in HIV-1 infected Chinese patients will provide valuable information for the design of vaccines to prevent HIV-1 transmission in China. Sera from a cohort of homosexual men, who have been managed by a major HIV clinical center in Beijing, China, were analyzed for cross-sectional neutralizing activities against pseudotyped viruses expressing Env antigens of the major subtype viruses (AE, BC and B subtypes) circulating in China. Neutralizing activities in infected patients' blood were most capable of neutralizing viruses in the homologous subtype; however, a subset of blood samples was able to achieve broad neutralizing activities across different subtypes. Such cross neutralizing activity took 1-2 years to develop and CD4 binding site antibodies were critical components in these blood samples. Our study confirmed the presence of broadly neutralizing sera in China's HIV-1 patient population. Understanding the specificity and breadth of these neutralizing activities can guide efforts for the development of HIV vaccines against major HIV-1 viruses in China.

Indexed as

AdultAmino Acid SequenceAntibodies, NeutralizingAntibody SpecificityAntigens, ViralCD4 Lymphocyte CountChinaCohort StudiesCross Reactionsenv Gene Products, Human Immunodeficiency VirusHIV-1HIV AntibodiesHIV InfectionsHomosexuality, MaleHumansMaleAntibodies, NeutralizingAntigens, Viralenv Gene Products, Human Immunodeficiency VirusHIV Antibodies

Identifiers

PMID23094060
PMCPMC3475692
OpenAlexW2018754025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.